OTC: SGMO
SANGAMO THERAPEUTICS, INCCIK 0001001233 · Health Care · SIC 2836 · Biological Products
Each report below shows a 3-bullet preview. Free accounts read 3 full reports a month — narrative summary, section diffs, and EDGAR-cited quotes.
Sign up freeWant to see a complete report first? Today's free report (NAVI 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade SGMO commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed May 14, 2026 (period ending Mar 31, 2026). SEC XBRL (companyfacts) — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Q3 ended Sep 30, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 1.4 | 0.6 |
| Operating expenses: | ||
| Research and development | 26.6 | 28.1 |
| General and administrative | 6.8 | 8.0 |
| Total operating expenses | 33.4 | 36.1 |
| Operating income | (31.9) | (35.6) |
| Other income/(expense), net | 0.7 | 0.1 |
| Income before income taxes | (31.0) | (35.1) |
| Income tax expense/(benefit) | — | (0.2) |
| Net income | (31.0) | (34.9) |
| Basic earnings per share | (0.08) | (0.11) |
| Diluted earnings per share | (0.08) | (0.11) |
Consolidated Balance Sheets (Unaudited)
| Description | Mar 31, 2026 | Dec 31, 2025 |
|---|---|---|
| Current assets: | ||
| Cash and equivalents | 27.6 | 20.9 |
| Accounts receivable, net | 0.9 | 0.4 |
| Prepaid expenses and other current assets | 3.2 | 4.4 |
| Other current assets | 5.5 | 10.1 |
| Total current assets | 37.1 | 35.8 |
| Property, plant and equipment, net | 10.3 | 11.0 |
| Operating lease right-of-use assets, net | 2.9 | 3.1 |
| Deferred income taxes and other assets | 0.9 | 0.9 |
| Other long-term assets | 8.8 | 8.9 |
| TOTAL ASSETS | 60.0 | 59.7 |
| Current liabilities: | ||
| Accounts payable | 19.3 | 14.4 |
| Accrued liabilities | 15.1 | 9.4 |
| Deferred revenue, current | 0.4 | 0.9 |
| Other current liabilities | 18.3 | 17.7 |
| Total current liabilities | 53.1 | 42.5 |
| Operating lease liabilities | 19.3 | 25.1 |
| Deferred income taxes and other liabilities | 0.6 | 0.6 |
| Other long-term liabilities | 5.9 | 5.9 |
| Total liabilities | 78.9 | 74.0 |
| Shareholders' equity: | ||
| Common stock | 4.1 | 3.5 |
| Capital in excess of stated value | 1,638 | 1,611 |
| Accumulated other comprehensive income (loss) | (2.5) | (1.5) |
| Retained earnings (deficit) | (1,658) | (1,627) |
| Total shareholders' equity | (19.0) | (14.3) |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | 60.0 | 59.7 |
Consolidated Statements of Cash Flows (Unaudited)
| Description | Q1 ended Mar 31, 2026 | Nine months ended Sep 30, 2025 |
|---|---|---|
| Operating Activities: | ||
| Net cash from operating activities | (19.3) | (72.8) |
| Investing Activities: | ||
| Net cash from investing activities | (0.01) | (0.09) |
| Financing Activities: | ||
| Net cash from financing activities | 26.7 | 56.0 |
| Net increase/(decrease) in cash | 6.6 | (12.9) |
Amounts in millions USD; EPS as reported. Line labels are presentation-friendly mappings of filer XBRL tags — not a re-audit of the full statements. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗